Trial Profile
An Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SBI-087 Administered to Japanese Subjects With Rheumatoid Arthritis.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs SBI 087 (Primary) ; SBI 087 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 15 Jun 2012 Actual end date (1 May 2012) added as reported by ClinicalTrials.gov.
- 15 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Apr 2012 Planned end date changed from 1 Mar 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.